[go: up one dir, main page]

MX2010001583A - Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. - Google Patents

Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2010001583A
MX2010001583A MX2010001583A MX2010001583A MX2010001583A MX 2010001583 A MX2010001583 A MX 2010001583A MX 2010001583 A MX2010001583 A MX 2010001583A MX 2010001583 A MX2010001583 A MX 2010001583A MX 2010001583 A MX2010001583 A MX 2010001583A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Application number
MX2010001583A
Other languages
English (en)
Inventor
Verena Lutz
Paul Delmar
Barbara Klughammer
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001583A publication Critical patent/MX2010001583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un biomarcador que es predictivo para el beneficio clínico del tratamiento con un inhibidor del EGFR en pacientes con cáncer.
MX2010001583A 2007-08-14 2008-08-07 Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. MX2010001583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114302 2007-08-14
PCT/EP2008/006523 WO2009021684A2 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
MX2010001583A true MX2010001583A (es) 2010-03-15

Family

ID=40227562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001583A MX2010001583A (es) 2007-08-14 2008-08-07 Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Country Status (14)

Country Link
US (2) US20110184005A1 (es)
EP (1) EP2176430B9 (es)
JP (1) JP5368445B2 (es)
KR (1) KR101169246B1 (es)
CN (1) CN101827947B (es)
AU (1) AU2008286337B2 (es)
CA (1) CA2695473C (es)
DK (1) DK2176430T5 (es)
ES (1) ES2395881T3 (es)
IL (1) IL203647A (es)
MX (1) MX2010001583A (es)
PL (1) PL2176430T3 (es)
SI (1) SI2176430T1 (es)
WO (1) WO2009021684A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969174B1 (fr) 2010-12-16 2014-03-14 Commissariat Energie Atomique Ligand specifique de la proteine lar

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5795716A (en) * 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
GB0312451D0 (en) * 2003-05-30 2003-07-09 Astrazeneca Uk Ltd Process
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20060234237A1 (en) * 2004-01-08 2006-10-19 Amler Lukas C Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Also Published As

Publication number Publication date
PL2176430T3 (pl) 2013-02-28
CA2695473A1 (en) 2009-02-19
KR20100037634A (ko) 2010-04-09
WO2009021684A3 (en) 2009-04-16
JP2010535524A (ja) 2010-11-25
DK2176430T5 (da) 2013-09-08
BRPI0815543A2 (pt) 2013-03-12
CA2695473C (en) 2013-10-01
AU2008286337A1 (en) 2009-02-19
EP2176430B9 (en) 2013-07-24
CN101827947A (zh) 2010-09-08
JP5368445B2 (ja) 2013-12-18
SI2176430T1 (sl) 2013-01-31
CN101827947B (zh) 2013-11-13
EP2176430B1 (en) 2012-09-19
US9121067B2 (en) 2015-09-01
WO2009021684A2 (en) 2009-02-19
US20110184005A1 (en) 2011-07-28
DK2176430T3 (da) 2012-10-08
US20130210843A1 (en) 2013-08-15
IL203647A (en) 2013-02-28
EP2176430A2 (en) 2010-04-21
AU2008286337B2 (en) 2011-10-27
KR101169246B1 (ko) 2012-08-03
ES2395881T3 (es) 2013-02-15
ES2395881T9 (es) 2013-09-06

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA201171367A1 (ru) Винилиндазолильные соединения
IN2012DN03012A (es)
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
CR9301S (es) Cuerpo de grifo
MX2013003880A (es) Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama.
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
FR2912304B1 (fr) Instrument de reduction de fracture de corps osseux.
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001573A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001583A (es) Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
BR112013009143A2 (pt) método in vitro, uso e invenção
MX2010001570A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001572A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001579A (es) Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
MX2010001580A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
FG Grant or registration